摘要
乙型肝炎病毒(HBV)感染是重大的全球公共卫生问题,据世界卫生组织估计,截至2025年,全球约有2.57亿慢性HBV感染者。目前,慢性HBV感染治疗药物主要是核苷(酸)类似物和聚乙二醇干扰素(PEG-IFN)。然而,从以往的研究结果来看,不论是核苷(酸)类似物和PEG-IFN-α单药、联合还是序贯联合治疗,患者的乙型肝炎表面抗原血清学转换率均较低,接受一定疗程的抗病毒治疗后仍具有较大的疾病进展风险。因此,为了达到世界卫生组织制定的"2030年消除病毒性肝炎"宏伟目标,帮助更多乙型肝炎患者实现功能性治愈,大量的新药被开发并进入临床试验研究。现对慢性HBV感染治疗新型药物的类型、安全性和疗效进行总结综述,以推动其在慢性HBV感染治疗领域的进一步发展。
Hepatitis B virus(HBV)infection is a major global public health problem.There will be about 257 million chronic HBV-infected patients worldwide,according to the World Health Organization's estimation by 2025.Currently,the main drugs for the treatment of chronic HBV infection are nucleos(t)ide analogues and pegylated interferon(PEG-IFN).However,previous research results show that whether it is nucleos(t)ide analogues and PEG-IFN-α monotherapy or combination therapy,or sequential combination therapy,the rate of hepatitis B surface antigen seroconversion in patients is low,and there is still a high risk of disease progression after a certain course of antiviral treatment.Therefore,to achieve the ambitious target of"eliminating viral hepatitis by 2030"set by the World Health Organization and help more hepatitis B patients achieve functional cure,a large number of new drugs have been developed and entered clinical trials.This paper summarizes and reviews the types,safety,and efficacy of new drugs to further promote advancements in the field of treatment of chronic HBV infection.
作者
余滢滢
李静
王文鑫
樊佩瑶
王福生
Yu Yingying;Li Jing;Wang Wenxin;Fan Peiyao;Wang Fusheng(The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Senior Department of Infectious Diseases,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China;Tsinghua-Peking Center for Life Sciences,Tsinghua University,Beijing 100039,China;Peking University 302 Clinical Medical School,Beijing 100039,China)
出处
《中华肝脏病杂志》
北大核心
2025年第5期493-499,共7页
Chinese Journal of Hepatology
基金
国家重点研发计划(2022YFA1303603)。
作者简介
通信作者:王福生,Email:fswang302@163.com。
